Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Current Leases: 2023-2025

Historic Current Leases for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $3.1 million.

  • Artiva Biotherapeutics' Current Leases fell 14.31% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 14.31%. This contributed to the annual value of $3.6 million for FY2024, which is 0.61% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Current Leases of $3.1 million as of Q3 2025, which was down 12.42% from $3.5 million recorded in Q2 2025.
  • Artiva Biotherapeutics' Current Leases' 5-year high stood at $3.7 million during Q2 2024, with a 5-year trough of $3.1 million in Q3 2025.
  • Moreover, its 3-year median value for Current Leases was $3.6 million (2023), whereas its average is $3.5 million.
  • Per our database at Business Quant, Artiva Biotherapeutics' Current Leases rose by 0.61% in 2024 and then decreased by 14.31% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Current Leases (Quarterly) stood at $3.6 million in 2023, then grew by 0.61% to $3.6 million in 2024, then declined by 14.31% to $3.1 million in 2025.
  • Its Current Leases stands at $3.1 million for Q3 2025, versus $3.5 million for Q2 2025 and $3.6 million for Q1 2025.